FLT3 and acute myeloid leukemia: The approval of first-generation FLT3i midostaurin, based on improved overall survival (OS) in the phase III RATIFY trial, established the addition of midostaurin to induction therapy as a standard approach in newly diagnosed FLT3-mutated AML [3].